Paul England writes on COVID-19 drug supply and patent system for Manufacturing Chemist

The patent system has come under pressure both politically and, more recently, as pharma companies scale-up their operations to make large amounts of drugs available to treat COVID-19.

Paul England outlines what leverage governments have in international negotiations for supplies, particularly when drugs are covered by patents that give them or their chosen licensees the exclusive right to manufacture.

Read the full article on Manufacturing Chemist's website